Vivos Reports 7% Sales Drop

Vivos Therapeutics (NASDAQ:VVOS), the medical technology firm developing non-surgical treatments for obstructive sleep apnea (OSA), reported its second-quarter 2025 results on August 20, 2025. The central news was a strategic shift following its acquisition of The Sleep Center of Nevada, alongside a move away from dentist-driven sales and toward direct alliances with medical providers. Revenue landed at $3.8 million, yet down from the prior year, and gross margin fell sharply to 55%, with expenses rising due to integration and financing costs. Management flagged these as expected transition results, leaving the period defined by a business in flux and growing financial pressures. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Vivos Therapeutics develops and markets oral appliances designed to treat obstructive sleep apnea, a condition where a person’s airway frequently collapses or becomes blocked during sleep. Its proprietary approach, branded as the "Vivos Method," is a non-surgical alternative aimed at repositioning and expanding the airway, targeting adults and children who are unsuitable or non-compliant with traditional continuous positive airway pressure (CPAP) therapies. The company's treatment platform is cleared by the U.S. Food and Drug Administration for moderate to severe OSA, which helps set it apart in a crowded market.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool